A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

NCT07033494 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

340

Enrollment

INDUSTRY

Sponsor class

Conditions

Early Alzheimer's Disease

Interventions

BIOLOGICAL: MK-2214
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC